Sanofi and Boehringer Ingelheim sign strategic collaboration agreement to manufacture biological products
<p>Sanofi will gain access to the German company’s facilities to transfer and manufacture mAb therapeutics</p>
In order to expand Sanofi’s manufacturing capacity and thus support upcoming product launches, Boehringer Ingelheim and Sanofi have signed a strategic collaboration agreement to manufacture therapeutic monoclonal antibodies.
This alliance will give the pharmaceutical company access to the Boehringer Ingelheim facilities in Bibereach an der Riß, Germany, to transfer and manufacture mAb therapeutics. Although the financial terms of the agreement have not yet been disclosed, the first products will be transferred early this year.
Wolfram Carius, senior vice-president of Biological Products at Sanofi, explains that this collaboration will complement the alliance the company already has with Regeneron and its investment in internal facilities. Moreover, he explains that they are preparing “for a wave of new product launches over the coming years.”
Senior Corporate Vice-President of Boehringer Ingelheim Biopharmaceuticals Uwe Bücheler highlighted that the agreement reflects the German company’s strategic commitment to manufacturing innovative new biological products.
Both Sanofi and Boehringer Ingelheim have their Spanish headquarters in Catalonia.